Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novo Holdings
Pharma
Paratek buys Optinose, rhinosinusitis spray Xhance for up to $330M
In a move to expand its portfolio beyond antibiotics, Paratek has bought out Optinose and its chronic rhinosinusitis nasal spray Xhance for $330M.
Kevin Dunleavy
Mar 20, 2025 11:23am
Novo Nordisk figures sales growth will slow slightly in 2025
Feb 5, 2025 11:43am
2024's top biopharma M&A deals
Jan 13, 2025 3:00am
Novo Holdings' $16.5B Calalent buyout to close in 'coming days'
Dec 16, 2024 11:51am
European officials approve Novo Holdings' planned Catalent buy
Dec 6, 2024 2:48pm
Roche CEO critiques Novo's proposed Catalent buyout
Oct 23, 2024 12:35pm
